Please login to the form below

Not currently logged in
Email:
Password:

BAN2401

This page shows the latest BAN2401 news and features for those working in and with pharma, biotech and healthcare.

Biogen, Eisai take Alzheimer’s candidate BAN2401 into phase 3

Biogen, Eisai take Alzheimer’s candidate BAN2401 into phase 3

The study will evaluate the therapeutic effect of BAN2401 on the progression of Alzheimer’s disease (AD) in individuals in preclinical, asymptomatic stages of the disease. ... Biogen and Eisai are also currently studying BAN2401 in a pivotal phase 3

Latest news

More from news
Approximately 2 fully matching, plus 13 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics